<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24612193</PMID>
<DateCompleted>
<Year>2015</Year>
<Month>05</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>08</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1440-1789</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Neuropathology : official journal of the Japanese Society of Neuropathology</Title>
<ISOAbbreviation>Neuropathology</ISOAbbreviation>
</Journal>
<ArticleTitle>Cerebral and spinal cord tanycytic ependymomas in a young adult with a mutation in the NF2 gene.</ArticleTitle>
<Pagination>
<MedlinePgn>406-13</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/neup.12109</ELocationID>
<Abstract>
<AbstractText>We studied one frontal lobe tumor and multiple spinal cord tumors (one in an extramedullary location) that had been resected from a 24-year-old man. The frontal lobe tumor was well demarcated and non-infiltrating, and consisted of eosinophilic, elongated fibrillary cells arranged in a fascicular pattern. A similar histology was reproduced in the spinal cord tumors, with additional areas showing standard features of ependymoma. Immunohistochemical and ultrastructural observations revealed that all the tumors were ependymal in nature with positivity for GFAP and epithelial membrane antigen and negativity for oligodendrocyte transcription factor 2, showing intra- and intercellular microrosettes, leading us to a diagnosis of tanycytic ependymoma for the frontal lobe tumor and tanycytic ependymoma with ordinary ependymomatous component for the spinal cord tumors. The spinal extramedullary tumor was a schwannoma. Importantly, a heterozygous truncating mutation in the NF2 gene was identified in the blood lymphocytes from the patient. It is known that multiple nervous system tumors can occur in neurofibromatosis type 2 (NF2), which is caused by mutation in the NF2 gene, and that occurrence of ependymoma, including the tanycytic variant, can be associated with this genetic condition. The present case provides further information about the clinicopathology of tanycytic ependymoma with details of the immunohistochemical, ultrastructural and genetic features.</AbstractText>
<CopyrightInformation>Â© 2014 Japanese Society of Neuropathology.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kuga</LastName>
<ForeName>Yoshihiro</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, Ohnishi Neurological Center, Akashi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ohnishi</LastName>
<ForeName>Hideki</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kodama</LastName>
<ForeName>Yuji</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takakura</LastName>
<ForeName>Shuji</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hayashi</LastName>
<ForeName>Masato</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yagi</LastName>
<ForeName>Ryokichi</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fukutome</LastName>
<ForeName>Kenji</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Matsushima</LastName>
<ForeName>Ken</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Okamoto</LastName>
<ForeName>Kouichirou</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Taomoto</LastName>
<ForeName>Katsushi</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takahashi</LastName>
<ForeName>Hitoshi</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Australia</Country>
<MedlineTA>Neuropathology</MedlineTA>
<NlmUniqueID>9606526</NlmUniqueID>
<ISSNLinking>0919-6544</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025581">Neurofibromin 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004806">Ependymoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005625">Frontal Lobe</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025581">Neurofibromin 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013120">Spinal Cord Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">gene analysis</Keyword>
<Keyword MajorTopicYN="N">immunohistochemistry</Keyword>
<Keyword MajorTopicYN="N">neurofibromatosis type 2 (NF2)</Keyword>
<Keyword MajorTopicYN="N">tanycytic ependymoma</Keyword>
<Keyword MajorTopicYN="N">ultrastructure</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2013</Year>
<Month>11</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2014</Year>
<Month>01</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2014</Year>
<Month>01</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2014</Year>
<Month>3</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2014</Year>
<Month>3</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2015</Year>
<Month>5</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">24612193</ArticleId>
<ArticleId IdType="doi">10.1111/neup.12109</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>